Mikhail Blagosklonny’s Exploration Of TOR Signaling

As an esteemed Professor of Oncology at the Roswell Park Cancer Institute and a member of the Department of Cell Stress Biology, Mikhail Blagosklonny engages in groundbreaking research in targeted cancer therapies and anti-aging medicines.

Specifically, Blagosklonny’s research includes biogerontology and Target of Rapamycin (TOR) signaling, key components of his anticancer and anti-aging strategies.

His research focuses on the idea that while molecular damage occurs with aging, humans don’t live long enough to die from it. According to Research Gate, an advocate of the drug rapamycin, which is a rare bacterium from Eater Island, Mikhail Blagosklonny believes the drug is not only a cancer treatment; it is a potential fountain of youth that may postpone certain aging-related diseases and delay the effects of normal aging by putting cells into a stress-resistant mode.

While Mikhail Blagosklonny’s findings mirror that of other researchers, he has gone a step further, taking the drug himself to prove that there are no side effects. Since rapamycin has been available for 15 years with no serious side effects, Blagosklonny is eager to explore off-label uses that may significantly improve the lives of older individuals.

A graduate of the First Pavlov State Medical University of St. Petersburg, รง holds an M.D. in Internal Medicine and a PhD in Experimental Medicine and Cardiology. Blagosklonny’s previous positions including Associate Professor of Medicine at New York Medical College and Senior Scientist at Ordway Research Institute.

In addition to publishing more than 270 papers of his own, Blagosklonny is the editor-in-chief of three medical and scientific journal publications; Aging, Cell Cycle and Oncotarget.

Impact Journals reported that Mikhail Blagosklonny is also Associate Editor of Cancer Research, Autophagy, the International Journal of Cancer, American Journal of Pathology and PLOS ONE.

Anthony Petrello – Life At Nabors Industries And His Philanthropy

The President and CEO of Nabors Industries, Anthony Petrello are very professional in case of the day to day activities of the firm or his philanthropic activities. Under him, the major oil and gas drilling firm brought cutting edge and competitive technology to win business from across the world. Also, the works were completed in the in the stringent manner as any misses in quality can cost very much for the firm. Petrello knows the priorities better than anyone and hence when he formulate direction of the organization, professionalism, and organizational discipline makes a strong presence in the agenda.

Fondly called as Tony by his friends, Petrello joined Nabors Industries in 1991 as Chief Operating Officer. Since 2011, he was promoted to CEO and President of the firm. In 2012, Petrello became the chairman of the board of directors. His long years with Nabors, helped him to restructure the firm for better operation. He is a strong proponent of technology and implements the new technologies at first sight. His strategy has helped the firm to expand the operations across the world. Currently, the firm has drilling service operations in the Middle East, Africa, Far East and Americas. He also led the firm in diversifying the business and introduced directional drilling systems, software for rig reporting, well servicing, pressure pumping, etc. During his tenure as COO, he took care of some important acquisitions to expand the footprint of the firm.

Petrello believes that diversifying the services can bring more business for the firm and ensure the growth of the firm. In 2014, he made a major restructure in the management of the firm to give a new direction to the company. Under his leadership, there were many CSR activities initiated. It includes support to Komen Race for the Cure, Mentor Programs with Aldine Independent School District, setting up National Multiple Sclerosis Society to support fight against multiple sclerosis, etc., are few in the list. The firm also sponsored 2012 Wounded War Heroes Fishing Rodeo to support wounded veterans.

Apart from redefining the vision of the firm, he is very active in philanthropy. His motto is to be part of a change in the world. His involvement in charity campaigns and donations has been appreciated by many. He is the board member of Texas Children’s Hospital and supports the research and programs to address the requirements of children suffering from neurological disorders. He and his wife made a donation of $7 million to the Texas Children’s Hospital and also conducted some fundraising.